Using Dose Titration to Resolve Acne on Testosterone Cypionate
HealthRX.com
The label does not give an acne-specific dose schedule
Key numbers
- 50 to 400 mgLabeled replacement dose range for testosterone cypionate, the amount per injectionSource: dailymed.nlm.nih.gov, as cited Oct 30, 2026
- 2 to 4 weeksLabeled interval between testosterone cypionate injections in replacement dosingSource: dailymed.nlm.nih.gov, as cited Oct 30, 2026
- about 8 daysHalf-life of testosterone cypionate after an intramuscular injectionSource: dailymed.nlm.nih.gov, as cited Oct 30, 2026
- 4.0%Mean hematocrit rise with intramuscular enanthate or cypionate versus placebo, pooled estimateSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
From the public record
FDA adverse event reports naming acne and testosterone cypionate
Through 2026-10-28, FDA had received 36 adverse event reports for testosterone cypionate that name acne, out of 8,833 reports for the drug in all. 6 of these reports concerned female patients and 27 male patients.
| Measure | Value | Note |
|---|---|---|
| Reports naming acne | 36 | |
| All reports for testosterone cypionate | 8,833 | |
| Share of this drug's reports naming it | 0.4% | share of reports received, not of people taking the drug |
| Of those: female patients | 6 | reflects who takes the drug and who files reports |
| Of those: male patients | 27 | |
| Of those: sex not recorded | 3 |
How this was calculated
Counted FAERS reports listing this active substance and at least one of these reaction terms: acne. A report can name several reactions and several drugs. Counts by year use the date FDA received the report.
Reports where FDA recorded testosterone cypionate as a single-ingredient active substance (any brand), MedDRA term acne
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.
From the public record
Most reported events in FDA adverse event reports for testosterone cypionate
Through 2026-10-28, FDA had received 8,833 adverse event reports for testosterone cypionate, 5,064 of them marked serious by the reporter. The symptom terms named most often were myocardial infarction (953), cerebrovascular accident (685) and deep vein thrombosis (624).
| Measure | Value | Note |
|---|---|---|
| All reports received | 8,833 | |
| Reports the reporter marked serious | 5,064 | death, hospitalisation, disability or similar outcome |
| Myocardial infarction | 953 reports | |
| Cerebrovascular accident | 685 reports | |
| Deep vein thrombosis | 624 reports | |
| Pulmonary embolism | 572 reports | |
| Pain | 474 reports |
How this was calculated
Counted FAERS reports listing this active substance, then the reaction terms named most often. A report can name several reactions, and a term can describe the illness being treated and not an effect of the drug. Terms about product use or complaints rather than symptoms (for example drug ineffective) were left out of the list.
Reports where FDA recorded testosterone cypionate as a single-ingredient active substance (any brand), all years to 2026-10-28
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.
From the public record
FDA label facts for testosterone cypionate
The FDA label read for testosterone cypionate (AZMIRO, application NDA216318) was last revised on 2025-07-25. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2025-07-25 | |
| Label read | AZMIRO | NDA216318, brand-name application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient testosterone cypionate from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
At a glance
- Acne on the cypionate label / listed under skin and appendages reactions, with no rate given [1]
- Labeled replacement dose / 50 to 400 mg intramuscularly every 2 to 4 weeks [1]
- Basis for dose adjustment / the patient's response and the appearance of adverse reactions [1]
- Half-life after intramuscular injection / about 8 days [1]
- Acne as a recognized testosterone effect / listed among undesired effects of therapy in a 2017 review of transgender men [2]
- Monitoring in the first year / symptoms, serum testosterone, hematocrit, prostate cancer risk [3]
- Hematocrit with intramuscular enanthate or cypionate / pooled mean rise 4.0% versus placebo in a review of 29 randomized trials (3,393 men) [4]
What the cypionate label says about acne and dose
Depo-Testosterone's adverse reactions section lists acne in a short skin list alongside hirsutism, male pattern baldness and seborrhea, with no frequency attached [1]. The dosage section says the suggested dose varies with age, sex and diagnosis, that dosage is adjusted according to the patient's response and the appearance of adverse reactions, and that replacement dosing runs from 50 to 400 mg every 2 to 4 weeks [1].
Two variables sit inside the label: the amount, 50 to 400 mg, and the interval, 2 to 4 weeks [1]. The label gives no acne-specific step size and no expected time for skin to improve after a dose change, and it does not identify a serum testosterone level at which acne does or does not occur [1].
HealthRX.com offers testosterone cypionate by prescription.
How often does acne happen on testosterone?
A 2017 review in Lancet Diabetes & Endocrinology of testosterone therapy for transgender men lists acne among the undesired effects, alongside alopecia, reduced HDL cholesterol, increased triglycerides and a possible rise in systolic blood pressure [2]. That review covers a different treated population, men aiming for a male reference range rather than men treated for hypogonadism, so it confirms acne as a recognized effect of testosterone therapy rather than supplying a rate.
Injection timing and the label
Testosterone esters in oil are absorbed slowly from the lipid phase, which is why testosterone cypionate can be given at intervals of two to four weeks; the label gives a half-life of about 8 days after an intramuscular injection [1]. The label does not say whether changing the injection interval improves acne [1].
What people on Reddit report
Reddit replies from people on testosterone injections describing how dose changes, injection frequency or the cypionate ester seemed to affect their acne. Experiences vary and none are clinical data.
Ive rarely heard of the ester being the issue. Injection frequncy has a big impact. It prevent peaks and valleys in your horomone levels = less acne.Read the source discussion
It started happening around my chin/jaw area once my doctor changed my dose of testosterone higher and then lower again. For some reason that change really triggered it imo.Read the source discussion
I tried adding in a small dose of the cypionate, hoping I'd have a different outcome, and had big cysts again the next morning.Read the source discussion
What else gets checked when the dose changes
A dose change is also a checkpoint. The 2018 Endocrine Society guideline recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of therapy [3]. The cypionate label says to check hemoglobin and hematocrit periodically during long-term use and to monitor blood pressure periodically, especially in men with hypertension [1].
A review of 29 placebo-controlled trials involving 3,393 men compared several testosterone formulations. In its pooled estimate, intramuscular enanthate or cypionate raised mean hematocrit by 4.0% versus placebo [4].
Questions worth asking
Treating the acne itself
A 2021 editorial in the Journal of Drugs in Dermatology on isotretinoin prescribing for transgender patients opens with a 26-year-old on weekly intramuscular testosterone with severe nodulocystic scarring acne [7]. It is a call for guidance rather than an outcomes study, and it does not report what happened when isotretinoin was combined with a testosterone dose change.
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is acne a contraindication to testosterone cypionate?
What gets monitored when the dose changes?
What does the label say about changing the interval between cypionate injections?
What about isotretinoin for testosterone-related acne?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Depo-Testosterone (cypionate) intramuscular, Pharmacia & Upjohn/Pfizer (testosterone cypionate) prescribing information. Depo-Testosterone (cypionate) intramuscular, Pharmacia & Upjohn/Pfizer (testosterone cypionate) label
- Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301-311.
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
- Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51.
- Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in Male Physiology. Physiol Rev. 2017;97(3):995-1043.
- Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015;3(3):165-73.
- Sanchez DP, Brownstone N, Thibodeaux Q, Reddy V, Myers B, Chan S, et al. Prescribing Isotretinoin for Transgender Patients: A Call to Action and Recommendations. J Drugs Dermatol. 2021;20(1):106-108.
- Reddit participants. Cystic acne (r/TRT_females). Accessed 2026-11-11.